" class="no-js "lang="en-US"> harrison.ai - Medtech Alert
Monday, August 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
harrison.ai | Pharmtech Focus

harrison.ai

About harrison.ai

harrison.ai

In 2018, brothers Dimitry Tran and Dr Aengus Tran founded harrison.ai and began their journey to create accurate and clinically effective medical AI solutions.

Today harrison.ai has over 250 staff working across harrison.ai and its ventures.

Our mission to create AI-as-a-medical-device solutions that improve the standard of healthcare for 1million lives every day is shared by our staff, suppliers, investors and customers.

With investment from Horizons Ventures, Blackbird Ventures and Skip Capital, harrison.ai is on track to deliver accessible healthcare solutions to the world.